<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02599168</url>
  </required_header>
  <id_info>
    <org_study_id>EC/04/15/807</org_study_id>
    <nct_id>NCT02599168</nct_id>
  </id_info>
  <brief_title>Effect of Dexmedetomidine on Propofol Requirement During Anesthesia</brief_title>
  <official_title>The Effect of Dexmedetomidine on Propofol Requirements During Anesthesia Administered by Bispectral Index-Guided Closed-Loop Anesthesia Delivery System: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr Nitin Sethi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sir Ganga Ram Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dexmedetomidine, a selective alpha-2 agonist agent used for maintaining sedation in intensive&#xD;
      care patients in receipt of mechanical ventilation, is being increasingly utilized in&#xD;
      anaesthesia practice for facilitating anaesthesia depth as an adjunct to base anaesthetics&#xD;
      (intravenous; propofol: inhalational; sevoflurane, desflurane). The investigators intend to&#xD;
      assess the anaesthetic potential of dexmedetomidine in controlled anaesthesia settings&#xD;
      empowered by the use of an objective, patient response based, safe, efficient, and patented&#xD;
      closed loop anaesthesia delivery system (CLADS). CLADS functions on control of processed EEG&#xD;
      response parameter captured from anaesthetized patients with the help of a BIS- monitor,&#xD;
      which is continuously fed into a automated drug infusion pump. The infusion pump then&#xD;
      accordingly delivers the anaesthetic drug to the patients based on pharmacodynamic&#xD;
      requirements. If dexmedetomidine has anaesthesia potential then it is likely that propofol&#xD;
      use delivered by CLADS can be reduced further. In addition the effect of two drugs (viz, base&#xD;
      agent-propofol plus adjunct agent-dexmedetomidine) on different receptor site within the&#xD;
      brain would help gain greater anaesthetic depth consistency as well as a lower incidence of&#xD;
      intraoperative patient awareness. This prospective randomized two-arm study aims to assess&#xD;
      effect of the use of dexmedetomidine on propofol requirements (primary objective),&#xD;
      anaesthesia depth consistency, and intraoperative patient awareness (secondary objectives).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After Institutional Ethics Committee approval and written informed consent, eighty&#xD;
      patient-participants (40 per group) aged 20-65 years, ASA physical status I/II, of either&#xD;
      sex, and undergoing major laparoscopic / robotic surgery of more than 60-minutes duration&#xD;
      will be included in this single-center (Sir Ganga Ram Hospital, New Delhi-110060, India )&#xD;
      prospective, double-blinded, two-arm, randomized controlled study.&#xD;
&#xD;
      The patients will be randomly divided into two groups:&#xD;
&#xD;
      Group-I: Pre-induction dexmedetomidine + intraoperative dexmedetomidine plus anesthesia with&#xD;
      propofol delivered by CLADS (induction + maintenance) [Dexmedetomidine group] Group-II:&#xD;
      Pre-induction 0.9% saline solution + intraoperative 0.9% saline solution infusion +&#xD;
      anesthesia with propofol delivered by CLADS (induction + maintenance) [Non Dexmedetomidine&#xD;
      group]&#xD;
&#xD;
      Sample-size Estimation:&#xD;
&#xD;
      The sample size estimation was estimated from the cue that the average propofol doses&#xD;
      required for maintenance of anaesthesia (4.7+ 1.6 mg/kg/hr) when using manual propofol and&#xD;
      remifentanil target controlled infusion18 with a 90% power employed to detect a 30% decrease&#xD;
      of propofol dosage among the patients who will receive dexmedetomidine in addition to base&#xD;
      anesthetic propofol; with a bilateral α risk value of 0.05, the investigators would require&#xD;
      66 patients for the study. To cover up for unanticipated losses the investigators would need&#xD;
      additional 20% patients. Thus the investigators would require 80-patients for the study&#xD;
&#xD;
      Randomization, Allocation Concealment:&#xD;
&#xD;
      The patients will be randomly allocated to one of the two groups based on a&#xD;
      computer-generated random number table&#xD;
      (url:stattrek.com/statistics/random-number-generator.aspx). Randomization sequence&#xD;
      concealment will include opaque-sealed envelopes with alphabetic codes whose distribution&#xD;
      will be in control of an independent analyst. The envelopes will be opened; patient's&#xD;
      data-slip will be pasted on them, and will be sent back to the control analyst.&#xD;
&#xD;
      Management of Anaesthesia:&#xD;
&#xD;
      Two peripheral venous lines (18G/20G catheter) will be secured. Invasive vascular access&#xD;
      (arterial line for direct continuous blood pressure assessment, central venous catheter) will&#xD;
      be secured as per the requirement of surgery and/or patients morbid status. A BIS sensor&#xD;
      (Covidien IIc, Mansfield, USA) for monitoring depth of anaesthesia, using the BIS monitoring&#xD;
      module (Model DSC-XP, Aspect medical system, USA), will be applied over the patient's&#xD;
      forehead according to manufacturer's instruction prior to induction of anaesthesia.&#xD;
&#xD;
      The patients will be randomly allocated to one of the two groups separated by method of&#xD;
      dexmedetomidine administration. The pre-induction and the infusion dose of dexmedetomidine&#xD;
      will be 1-µ/kg over 10 minutes and 0.5-µ/kg/hour, respectively. Dexmedetomidine infusion will&#xD;
      be stopped in case of acute haemodynamic suppression (&gt;20% pre-induction baseline) or acute&#xD;
      blood loss (&gt;200-ml) at any point of time and it will be recorded as an event. It will be&#xD;
      restarted upon normalcy of haemodynamics is achieved and also full surgical hemostasis is&#xD;
      ensured.&#xD;
&#xD;
      Anesthesia Technique:&#xD;
&#xD;
      All the patients will be administered pre-induction fentanyl-citrate analgesia as per a&#xD;
      predefined strategy (total 2-µg/kg IV: 1-µg/kg at 0 minute, 3-minutes time points].&#xD;
      Pre-oxygenation will be initiated at 6-minute time point or prior to that if there is a fall&#xD;
      in oxygen saturation &lt; 94 percent. At 9-minute time point anaesthesia will be induced with&#xD;
      propofol 2-mg/kg and vecuronium bromide 0.08-mg/kg for skeletal muscle relaxation to&#xD;
      facilitate tracheal intubation. Ventilator settings of CMV, tracheal tube size [7.5-mm I.D&#xD;
      (male), 6.5-mm I.D (female)] and breathing circuit (circle-CO2 absorber system) will be the&#xD;
      standardized in all the patients. Routine monitoring (EKG, NIBP, pulse oximetery, EtCO2) will&#xD;
      be applied during the procedure as per the established practice. Over and above the use of&#xD;
      study drug dexmedetomidine as per group allocation, propofol administration will be&#xD;
      controlled with CLADS system tuned to consistent anaesthetic depth (BIS 40-60) in all the&#xD;
      patients. In addition, all the patients will receive 0.5-µg/kg/hr fentanyl infusion during&#xD;
      surgery. Oxygen.-air mixture (FiO2 0.50) will be utilized for intraoperative ventilation.&#xD;
      Neostigmine (50-µg/kg) and glycopyrrolate (20-µg/kg) will be administered to reverse the&#xD;
      residual neuromuscular blockade (non-depolariser).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 5, 2015</start_date>
  <completion_date type="Actual">March 20, 2017</completion_date>
  <primary_completion_date type="Actual">March 20, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Propofol usage in milligrams</measure>
    <time_frame>From beginning of anaesthesia (0-hours, baseline) till 6 hours intraoperatively</time_frame>
    <description>Comparison of 'dexmedetomidine' versus 'no dexmedetomidine' administration in decreasing quantitative propofol requirements (measured in milligrams) during closed loop anaesthesia delivery system empowered and Bi-spectral index controlled propofol-based general anaesthesia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of change in anaesthesia depth using Bi-spectral index score</measure>
    <time_frame>From beginning of anaesthesia (0-hours, baseline) till 6 hours intraoperatively</time_frame>
    <description>Comparison of anaesthesia depth adequacy in intervention (with dexmedetomidine) versus control (without dexmedetomidine) using Varvel criteria to assess Bi-spectral index (BIS) score consistency during closed loop anaesthesia delivery system empowered and BIS-controlled propofol-based general anaesthesia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Intraoperative heart Rate (beats per minute)</measure>
    <time_frame>From beginning of anaesthesia (0-hours, baseline) till 6 hours intraoperatively</time_frame>
    <description>Comparison of intraoperative heart rate in the 'intervention' (with dexmedetomidine) versus 'control' (without dexmedetomidine) during closed loop anaesthesia delivery system empowered and Bi-spectral index controlled propofol-based GA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Intraoperative blood pressure - systolic , diastolic, and mean (mmHg)</measure>
    <time_frame>From beginning of anaesthesia (0-hours, baseline) till 6 hours intraoperatively</time_frame>
    <description>Comparison of intraoperative blood pressure (systolic , diastolic, and mean) in the 'intervention' (with dexmedetomidine) versus 'control' (without dexmedetomidine) during closed loop anaesthesia delivery system empowered and Bi-spectral index controlled propofol-based GA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative sedation</measure>
    <time_frame>From the end of anaesthesia till 24-hours, postoperatively</time_frame>
    <description>Will be assessed using Observer asssesment of Alertness/Sedation Scale (OAAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative awareness</measure>
    <time_frame>From the end of anaesthesia till 48-hours, postoperatively</time_frame>
    <description>Will be assessed using modified brice questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative nausea and vomiting</measure>
    <time_frame>From the end of anaesthesia till 24-hours, postoperatively</time_frame>
    <description>Will be assessed using PONV scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Analgeisa</measure>
    <time_frame>From the end of anaesthesia till 24-hours, postoperatively</time_frame>
    <description>Will be assessed using Visual Analogue Scale (VAS) Score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive a pre-induction loading dose of dexmedetomidine 1-µ/kg over 10 minutes followed by an intraoperative infusion of 0.5-µ/kg/hour . Over and above the use of study drug dexmedetomidine propofol administration will be controlled with Closed Loop Anaesthesia Delivery system to maintain a consistent anaesthetic depth (BIS 40-60) using bispectral index monitor in all the patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Dexmedetomidine group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive a pre-induction loading dose of 0.9% saline solution over 10 minutes followed by an intraoperative infusion.Over and above the use of 0.9% saline solution propofol administration will be controlled with Closed Loop Anaesthesia Delivery system to maintain a consistent anaesthetic depth (BIS 40-60) using bispectral index monitor in all the patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <arm_group_label>Dexmedetomidine group</arm_group_label>
    <arm_group_label>Non-Dexmedetomidine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <arm_group_label>Dexmedetomidine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (normal saline)</intervention_name>
    <arm_group_label>Non-Dexmedetomidine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ASA physical status I/II&#xD;
&#xD;
          2. Undergoing elective laparoscopic / robotic surgery of more than 60-minutes duration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cardiovascular disorders (uncontrolled hypertension, Atrio-ventricular block, sinus&#xD;
             bradycardia, congenital heart disease, reduced LV compliance &amp; diastolic dysfunction)&#xD;
&#xD;
          2. Neurological disorders (previous neurosurgery, psychiatric disorders, autonomic&#xD;
             nervous system disorders- orthostatic hypotension, transient ischemic attacks)&#xD;
&#xD;
          3. Any hepato-renal insufficiency&#xD;
&#xD;
          4. Uncontrolled diabetes mellitus&#xD;
&#xD;
          5. Known allergy/hypersensitivity to study drug&#xD;
&#xD;
          6. Pulmonary dysfunction (restrictive /obstructive lung disease)&#xD;
&#xD;
          7. Acute/chronic drug dependence/substance abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Goverdhan D Puri, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Post Graduate Institute of Medical Education &amp; Research, Chandigarh, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jayashree Sood, MD, FFRCA</last_name>
    <role>Study Chair</role>
    <affiliation>Sir Ganga Ram Hospital, New Delhi, INDIA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amitabh Dutta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sir Ganga Ram Hospital, New Delhi, INDIA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sir Ganga Ram Hospital</name>
      <address>
        <city>New Delhi</city>
        <zip>110060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>October 28, 2015</study_first_submitted>
  <study_first_submitted_qc>November 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2015</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sir Ganga Ram Hospital</investigator_affiliation>
    <investigator_full_name>Dr Nitin Sethi</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>dexmedetomidine</keyword>
  <keyword>propofol</keyword>
  <keyword>BIS</keyword>
  <keyword>CLADS</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

